Akari Therapeutics Plc
AKTXNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for AKTX. That does not mean none is planned.
Get an email about AKTX's next catalysts
Track Akari Therapeutics (AKTX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 1 past
No catalysts found.
Market Overview
Stock performance and key metrics
Frequently asked questions
What is in Akari Therapeutics Plc's drug pipeline?β
CatalystAlert tracks 2 drug candidates in Akari Therapeutics Plc's (AKTX) pipeline across Phase 3, Phase 2. Its lead program is rVA576 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Akari Therapeutics Plc's next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for Akari Therapeutics Plc (AKTX) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track AKTX biotech catalysts?β
Add AKTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Akari Therapeutics Plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
